SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lighthouse who wrote (309)7/28/1998 10:45:00 AM
From: MCorbley  Read Replies (2) of 410
 
I believe that Genzyme's main earnings problem is that Seprafilm has not added $200 million to revenues as anticipated.

I recently had a chance conversation with an excellent abdominal surgeon and he had not heard of Seprafilm. However, when I told him about it, he was very interested and said that he would investigate it.

Perhaps surgeons are conservative as has been previously noted. Perhaps they are too busy to keep up on their reading. Perhaps they don't follow up on the long term side effects of surgery.

In any case, abdominal adhesions really are a BIG problem in major surgery. They are also a fundamental problem and it is unlikely that advances in surgical technique will eliminate them. Seprafilm appears to be a solution. It could be argued that Seprafilm should be a standard tool in most abdominal procedures. It simply hasn't caught on yet.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News